Home › Trial NCT07631871
An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy
- Trial IDNCT07631871
- StatusNot Yet Recruiting
- PhasePhase 2
- Study typeInterventional
- SponsorHaihua Yuan
- Enrollment10
- Start date2026-06-15
- ConditionsNeoplasms · Solid Tumors · HER2 Positive Solid Tumor · Endometrial Neoplasm · Urothelial Carcinoma (UC) · Pancreatic Neoplasms
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.